Abu Dhabi Recognises Abu Dhabi Stem Cells Center (ADSCC) as a Centre of Excellence in Hematopoietic Stem Cell Transplantation

By HEOR Staff Writer

April 5, 2023

Abu Dhabi Stem Cells Center (ADSCC), a subsidiary of PureHealth, has been named a centre of excellence in Hematopoietic Stem Cell Transplantation by the Department of Health – Abu Dhabi. The centre provides specialised and distinguished programmes with a high level of expertise and multidisciplinary resources, allowing it to conduct advanced medical procedures in specific clinical areas and conducting complex researches to provide the highest levels of care. The centre will provide an integrated and specialised range of surgical and non-surgical clinical services with world-class healthcare quality for patients who require hematopoietic stem cell transplantation for the treatment of blood diseases. To date, 13 cancer patients and one MS female patient have been treated by ADSCC under the AD-BMT programme.

Reference url

Recent Posts

Novartis oncology advancements
Novartis Oncology Advancements: Key Trial Findings and Market Implications

By HEOR Staff Writer

May 22, 2026

Novartis oncology advancements take center stage as the company prepares to unveil findings from more than 65 abstracts at the upcoming ASCO and EHA meetings. These presentations spotlight progress with Pluvicto, Kisqali, and Scemblix while reinforcing the firm’s commitment to transforming outcom...
Baxfendy hypertension treatment
Baxfendy Hypertension Treatment: FDA Approves First-in-Class Aldosterone Synthase Inhibitor
Baxfendy hypertension treatment received US Food and Drug Administration approval as the first aldosterone synthase inhibitor for adults with hypertension not adequately controlled on other antihypertensive medications. AstraZeneca’s Baxfendy (baxdrostat) demonstrated statistically significant an...
trastuzumab-deruxtecan reimbursement
Trastuzumab-Deruxtecan Reimbursement: A Careful Evaluation of Cost-Effectiveness for Advanced Gas...
Zorginstituut Nederland advises against routine trastuzumab-deruxtecan reimbursement for adults with HER2-positive gastric or gastro-oesophageal junction adenocarcinoma after two or more prior therapies, unless price negotiations secure at least a 62 percent reduction. The drug meets scientific s...